How to use the defective product report to notify a quality defect to the Romanian Drug Agency

How to use the defective product report to notify a quality defect to the Romanian Drug Agency

The Romanian Drug Agency (ANMDM) published on their website scientific decision No 4/24.10.2018 implementing the document of European Medicines Agency (EMA) on the defective product report (EMA/INS/GMP/35037/2017). Marketing authorisation holders (MAHs) have to report to ANMDM all the non-conformities related to the quality of medicinal products authorised in Romania under MRP/DCP or purely national procedure. […]

Bulgaria changes the structure of its ethics committees in clinical trials

Bulgaria changes the structure of its ethics committees in clinical trials

The Bulgarian Drug Law amendments published on 12-Oct-2018 introduced the biggest changes in the field of clinical trials in many years. Apart from synchronizing with Regulation (EU) No 536/2014 on clinical trials on medicinal products for human use, the national law amendments also completely restructure the national system of ethics committees. The ethics committees in […]

BDA: new requirements for the “proof of payment” document

BDA: new requirements for the “proof of payment” document

Starting in February 2018, the Bulgarian Drug Agency (BDA) applies additional requirements to the applicants when presenting proof of payment. These regard the fees paid for the administrative procedures managed by the BDA: marketing authorisations (MA) or registrations, variations, renewals of MA, transfer of MA, line-extensions, notification for changes in product information, parallel import, annual […]

The Bulgarian Drug Agency initiates PIC/S membership procedure

The Bulgarian Drug Agency initiates PIC/S membership procedure

The Bulgarian Drug Agency (BDA) announced that they will initiate the procedure to become a member of the Pharmaceutical Inspection Co-operation Scheme (PIC/S). PIC/S is a non-binding, informal co-operative arrangement between Regulatory Authorities in the field of Good Manufacturing Practice (GMP) of medicinal products for human or veterinary use. PIC/S aims at harmonising inspection procedures […]

BDA: Guidance on the implementation of safety features in Bulgaria

BDA: Guidance on the implementation of safety features in Bulgaria

Commission Delegated Regulation (EU) 2016/161 of 2 October 2015 supplemented Directive 2001/83/EC regarding the safety features appearing on the packaging of medicinal products for human use. In line with that, it is required that manufacturers place safety features consisting of a unique identifier (2D data matrix with a unique serial number) and an anti-tampering device […]

10 Years Anniversary

10 Years Anniversary

This November 2017 PharmDedict are proud to celebrate 10 years of service. In this period, we have supported over 100 renowned international and domestic companies. Our clients’ profile throughout the years covers a wide range of products: innovative pharmaceuticals, orphan drugs, radiopharmaceuticals, biological products, generic medicinal products, cosmetic products, food supplements, nutraceuticals and foods for […]

PharmDedict on Pharma Boardroom

PharmDedict on Pharma Boardroom

Pharma Boardroom goes deep into key country markets, conducting hundreds of exclusive interviews with the movers and shakers of the industry in order to outline the pharmaceutical industry trends and to provide news and reports intended for senior professionals who want to understand local and global markets. Here is what PharmDedict shared with them.  

EudraVigilance Go-Live: expecting 22 November 2017

EudraVigilance Go-Live: expecting 22 November 2017

The Announcement of the EMA Management Board earlier in May 2017 confirmed the full functionality of the EudraVigilance database. Hence, the transitional period in pharmacovigilance reporting in the EEA is about to expire. The simplified electronic reporting of suspected adverse reactions related to medicines by national competent authorities and marketing authorisation holders to EudraVigilance becomes […]

The first MRP with RMS Bulgaria is now on track

The first MRP with RMS Bulgaria is now on track

In May 2016 the Bulgarian Drug Agency (BDA) completed the first DCP with RMS Bulgaria. They now announced that in August 2016 the first mutual recognition procedure (MRP) will start with reference member state (RMS) Bulgaria and the concerned member state is Romania. Both procedures where the BDA acts for the RMS concern Bulgarian based […]